Hikal Limited has reported its financial results for the quarter and nine months ended December 31, 2025, demonstrating a clear return to operational profitability. The pharmaceutical and specialty chemicals company held its earnings conference call on February 11, 2026, providing comprehensive insights into its performance and strategic direction.

Financial Performance Overview

The company's consolidated performance for the reporting period reflects steady recovery across business segments:

The finance cost for Q3 FY26 decreased by 17% year-on-year due to lower debt levels and reduced interest rates. The company maintained its debt-equity ratio at 0.58 as of December 31, 2025.

Dividend Declaration and Corporate Actions

Hikal's Board of Directors approved an interim dividend of ₹0.2 per share (10% of face value) at their meeting on February 11, 2026. The company has set February 17, 2026 as the record date for determining shareholder eligibility for the interim dividend payment for FY 2025-26.

Pharmaceutical Segment Recovery

The Pharmaceutical division showed significant improvement with revenue of ₹337 crores and EBIT margin of 12.3% for Q3 FY26. The segment has successfully navigated regulatory challenges, with remediation measures substantially implemented following the U.S. FDA audit.

Key developments in the pharmaceutical business include:

• Supply resumptions progressing as per internal forecasts
• Strengthened quality management systems and processes
• Robust pipeline of niche molecules in oncology, CNS, and gastroenterology
• New high-potency laboratory and R&D centre operational in Pune
• Dual-site validation mandate for critical APIs to mitigate supply chain risks

Crop Protection and Diversification Strategy

The Crop Protection segment recorded revenue of ₹157 crores with an EBIT margin of 3% during the quarter. While facing persistent pricing pressures and structural overcapacity, the company is accelerating its portfolio diversification into specialty chemicals, particularly the Personal Care segment.

Strategic Investments and Future Outlook

Hikal has invested ₹100 crores in capital expenditure during the nine-month period, focusing on debottlenecking, regulatory upgrades, and expanding CDMO capacities. The company expects meaningful revenue from the Personal Care segment to commence in the next fiscal year.

The Animal Health business continues to gain traction with sustained momentum in outsourcing activities. The company maintains a master plan to build this into a ₹500 crores plus business over the next 4-5 years.

Management expressed confidence that the worst challenges of the past three years are behind them, with strengthened operations, enhanced quality systems, and diversified business segments positioning the company for sustainable growth in FY27 and beyond.

Source: Hikal Limited earnings call transcript

Hikal Limited announced its unaudited financial results for the third quarter and nine months ended December 31, 2025, reporting a net loss amid challenging market conditions. The company has now officially confirmed the record date for interim dividend payment following regulatory compliance requirements.

Financial Performance Overview

The company reported mixed financial performance with revenue growth but profitability challenges during the quarter.

For the nine months period, the company faced revenue decline with total revenue from operations at ₹11,932 million compared to ₹13,074 million in the previous year, representing a decrease of 8.7%.

Segment-wise Performance

Both business segments showed mixed results during the quarter:

The pharmaceuticals segment showed stronger growth momentum despite facing regulatory challenges, while the crop protection segment maintained steady performance.

Official Record Date Confirmation

Following the board meeting held on February 11, 2026, Hikal Limited has formally communicated the record date details to stock exchanges under Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company has notified Central Depository Services (India) Limited, National Securities Depository Limited, and registrar MUFG Intime India Private Limited regarding the record date fixation.

Dividend Declaration Details

The Board of Directors had earlier declared an interim dividend for shareholders:

Regulatory Compliance and Trading Window

The formal intimation was signed by Company Secretary & Compliance Officer Rajasekhar Reddy, ensuring compliance with regulatory requirements. The trading window for designated persons will reopen on February 14, 2026, following the closure since January 1, 2026.